Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
He is responsible for overseeing the globe-spanning effort to meet the tremendous demand for semaglutide, the GLP-1 drug Novo ...
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Wegovy and Ozempic — competing drugs from Novo Nordisk — remain on the FDA’s shortage list. With demand for GLP-1 drugs ...
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...
El Salvador will sell or discontinue wallet Chivo as part of deal. GDP revised higher. Micron stumbles and quantum computing ...
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The current regulatory environment in the U.S. tolerates overly large PBMs that engage in anticompetitive practices to accumulate excessive profits. Without strong competitors, dominant PBMs are free ...
That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them ...
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback